Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Evommune (EVMN) Interest Expenses (2024 - 2025)

Evommune (EVMN) has disclosed Interest Expenses for 2 consecutive years, with $9000.0 as the latest value for Q3 2025.

  • Quarterly Interest Expenses fell 47.06% to $9000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $25000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $50000.0 for FY2025, 35.14% up from the prior year.
  • Interest Expenses for Q3 2025 was $9000.0 at Evommune, up from -$1000.0 in the prior quarter.
  • The five-year high for Interest Expenses was $17000.0 in Q3 2024, with the low at -$1000.0 in Q4 2024.